We extended our assessment of the relationship between CHRNA5 SNPs and amyloid pathology into the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset, which uses different measurements of amyloid levels using brain positron emission topography (PET) or spinal tap sampling of cerebrospinal fluid (Supplementary Methods). Here, CHRNA5 is linked to Alzheimer disease.